Concerns about anaesthesia-related neurological injury in young children have been increasing among parents, health-care providers, and regulatory organisations. These concerns were first prompted by animal studies that showed accelerated apoptosis and neuronal death after exposure to general anaesthetic drugs. Most commonly used general anaesthetic drugs have since been found to cause pervasive adverse neurological effects in vitro and in immature animals, including non-human primates. This issue gained widespread prominence in 2017, when the US Food and Drug Administration issued a safety communication stating that the use of general anaesthetic drugs “for lengthy periods of time or over multiple surgeries or procedures may negatively affect brain development in children younger than 3 years”. Subsequently, warnings were added to the labels for these medicines.
Recent Posts
- 2024 Annual Meeting, presented by the International Anesthesia Research Society (IARS) and the Society of Critical Care Anesthesiologists (SOCCA), May 17-19, 2024, Seattle, WA
- Society for Pediatric Anesthesia (SPA) and the American Academy of Pediatrics (AAP), Pediatric Anesthesiology 2024, April 12-14, 2024, Anaheim, CA
- Duration of Fetoscopic Spina Bifida Repair Does Not Affect the Central Nervous System in Fetal Lambs.
- Melatonin attenuates sevoflurane-induced hippocampal damage and cognitive deficits in neonatal mice by suppressing CypD in parvalbumin neurons.
- Engeletin Ameliorates Sevoflurane-Induced Cognitive Impairment by Activating PPAR-Gamma in Neonatal Mice.